AB
Acesis BioMed is developing a platform of oral drug candidates targeting metabolic and endocrine disorders, with a primary focus on treating male hypogonadism through its lead candidate ACE-167, a non-steroidal therapy that stimulates testosterone production. This approach addresses the significant health issue of declining testosterone levels, which affect a substantial portion of the male population, particularly those with co-morbidities like type 2 diabetes.
Updated 4 months ago
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Features
- Acesis BioMed is developing a platform of oral drug candidates targeting metabolic and endocrine disorders, with a primary focus on treating male hypogonadism through its lead candidate ACE-167, a non-steroidal therapy that stimulates testosterone production. This approach addresses the significant health issue of declining testosterone levels, which affect a substantial portion of the male population, particularly those with co-morbidities like type 2 diabetes.